Unrivalled Devices Improve Procedural Success Rate

Publication Date: 21 March, 2022

Source: Headline Daily

The minimally invasive procedures for coronary and peripheral intervention are blessed with ongoing innovations and thus enabling physicians to treat more challenging cases that were not possible in the past. Technological advancements have allowed physicians to provide better medical treatment for patients and enhance their quality of life. Risk factors such as cholesterol, advanced age, hypertension, smoking, kidney disease are associated with the increased risk of developing calcification in the blood vessels in both heart and lower limbs. The blockages in the calcified blood vessels hardened and thus making it more difficult to treat.

We developed a scoring balloon that can dilate these calcified vessels, to improve both coronary and peripheral blood flow. The latest generation of our scoring balloon has an enhanced non-slip feature. In treating blood vessels that are totally blocked, we have developed a series of robust, low-profile balloons to help physicians to overcome these challenges.

In order to keep the vessel open, a drug eluting stent will be implanted. We offer the first dual-therapy stent in the market to reduce the risk of clot formation in the stent. For patients who suffer from heart attack, the use of dual-therapy stents may be beneficial to minimize the risk of bleeding due to prolonged medication. Backed by strong clinical data, a patient implanted with a dual-therapy stent has the flexibility to shorten the use of blood thinner drugs at the advice of physicians. In the treatment of peripheral artery disease, the goal is to restore blood flow to a limb for wound healing and hence rescuing the limb from the risk of amputation. We have a high-pressure balloon catheter to treat chronic limb ischemia that will enhance safety, effectiveness with high procedural success rate, thus saving a limb at risk.

A new treatment option has emerged for the treatment of tricuspid regurgitation (backflow of blood to right heart chamber). By implanting valves at the superior and inferior vena cava and without touching the tricuspid valve, patients who are very sick and not suitable for surgery and other treatment options can now be treated with this technology.

For over twenty years, OrbusNeich^® is excited to be a major contributor in the field of intravascular and structural heart therapies globally. Our passion is to establish a comprehensive product portfolio with innovations that benefit physicians and patients in years to come.